Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 8/20 | 1.00 |
| ▸ | VHL | P40337 | 2/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.35 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.35 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2566972 | 0.99 | EGLN2 (0.98) | EGLN2VHLEGLN1P4HTMPDE3B | |
| SCHEMBL4752172 | 0.84 | EGLN2 (0.73) | EGLN2VHLEGLN1P4HTMTET2 | |
| SCHEMBL4254990 | 0.84 | EGLN2 (0.72) | EGLN2EGLN1P4HTMPDE3BTET2 | |
| SCHEMBL4251308 | 0.84 | EGLN2 (0.72) | EGLN2EGLN1P4HTMPDE3BTET2 | |
| SCHEMBL8198455 | 0.83 | EGLN2 (0.71) | EGLN2EGLN1P4HTMTET2OGFOD1 | |
| Hydrochloric Acid SCHEMBL2569956 | 0.83 | EGLN2 (0.70) | EGLN2EGLN1P4HTMPDE3BTET2 | |
| SCHEMBL12997278 | 0.82 | EGLN2 (0.70) | EGLN2VHLEGLN1P4HTMTET2 | |
| SCHEMBL12997303 | 0.81 | EGLN2 (0.68) | EGLN2VHLEGLN1P4HTM | |
| SCHEMBL4752307 | 0.81 | EGLN2 (0.67) | EGLN2EGLN1P4HTMPDE3BTET2 | |
| Hydrochloric Acid SCHEMBL2572535 | 0.80 | EGLN2 (0.66) | EGLN2EGLN1P4HTMPDE3BTET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383269-B1 | Substituted Dihydropyrazolones for the treatment of cardiovascular diseases | BAYER IP GMBH (DE) | 2017-01-18 | — | — | EP | claimed |
| US-20160229858-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-08-11 | — | — | US | claimed |
| US-9168249-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-27 | — | — | US | claimed |
| US-20150148381-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-28 | — | — | US | claimed |
| US-8653111-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | claimed |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-17 | — | — | US | claimed |
| EP-2383269-B1 | Substituted Dihydropyrazolones for the treatment of cardiovascular diseases | BAYER IP GMBH (DE) | 2017-01-18 | — | — | EP | disclosed |
| US-20160229858-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160229858-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160229858-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-9168249-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9168249-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9168249-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2383269-A2 | Substituted Dihydropyrazolones for the treatment of cardiovascular diseases | Bayer Pharma AG (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-2383269-A2 | Substituted Dihydropyrazolones for the treatment of cardiovascular diseases | Bayer Pharma AG (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2008067871-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229858-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | EGLN2 250/4885VHL 6/4885EGLN1 828/4885 |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, HPGDS | EGLN2 44/4885VHL 5/4885EGLN1 219/4885 |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | EGLN2 250/4885VHL 6/4885EGLN1 828/4885 |
| US-20150148381-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | EGLN2 250/4885VHL 6/4885EGLN1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.